It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
Centre at Sree Chitra Tirunal Institute for Medical Sciences and Technology
Whole-genome sequencing to identify genetic mutation; epidemiological studies to help assess the distribution and mathematical modelling to forecast spread
MitraClip implants give a new lease of life for frail and elderly patients who cannot go in for conventional open-heart surgery
Dr.Reddy's will receive U.S. $6 million upfront upon closing followed by U.S. $9 million one year from closing
Subscribe To Our Newsletter & Stay Updated
